01:19 PM EST, 11/21/2025 (MT Newswires) -- Pasithea Therapeutics ( KTTA ) said Friday that ongoing phase 1/1b trial of PAS-004 in adult patients with neurofibromatosis type 1 showed more favorable pharmacokinetic properties in tablets versus capsules.

This enables a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced patient variability, the company said.

Shares of the company were down over 21% in recent Friday trading.

Price: 0.33, Change: -0.09, Percent Change: -21.13